Literature DB >> 16350417

Generation of HPV pseudovirions using transfection and their use in neutralization assays.

Christopher B Buck1, Diana V Pastrana, Douglas R Lowy, John T Schiller.   

Abstract

It has recently become possible to generate high-titer papillomavirus-based gene-transfer vectors. The vectors, also known as papillomavirus pseudoviruses (PsV), have been useful for studying papillomavirus assembly, entry, and neutralization, and may have future utility as laboratory gene-transfer tools or vaccine vehicles. This chapter outlines a simple method for production of PsV and their use in a high-throughput papillomavirus neutralization assay. The production method is based on transfection of a 293 cell line, 293TT, engineered to express high levels of SV40 large T antigen. The cells are co-transfected with codon-modified papillomavirus capsid genes, L1 and L2, together with a pseudogenome plasmid containing the SV40 origin of replication. Pseudogenome encapsidation within L1/L2 capsids is largely sequence independent, and plasmids entirely lacking PV sequences can be packaged efficiently, provided they are less than 8 kilobases in size. Non-infectious virus-like particles (VLPs) can also be produced after transfection of 293TT cells with L1 alone. Efficient purification of the PsV or VLPs is achieved by Optiprep (iodixanol) density gradient ultracentrifugation. Using these methods, it is possible to produce highly purified PsV with yields of at least 10(9) transducing units from a single 75-cm2 flask of cells. PsV encapsidating a secreted alkaline phosphatase (SEAP) reporter plasmid were used to develop a high-throughput in vitro neutralization assay in a 96-well plate format. Infection of 293TT cells is monitored by SEAP activity in the culture supernatant, using a highly sensitive chemiluminescent reporter system. Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA).

Entities:  

Mesh:

Year:  2005        PMID: 16350417     DOI: 10.1385/1-59259-982-6:445

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  165 in total

1.  Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.

Authors:  Manuela Donalisio; Marco Rusnati; Andrea Civra; Antonella Bugatti; Donatella Allemand; Giovanna Pirri; Andrea Giuliani; Santo Landolfo; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

2.  Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.

Authors:  Sara L Bissett; Dianna Wilkinson; Kate I Tettmar; Nicky Jones; Elaine Stanford; Gitika Panicker; Helena Faust; Ray Borrow; Kate Soldan; Elizabeth R Unger; Joakim Dillner; Philip Minor; Simon Beddows
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

3.  Phosphorylation of the Human Papillomavirus E2 Protein at Tyrosine 138 Regulates Episomal Replication.

Authors:  Leny Jose; Elliot J Androphy; Marsha DeSmet
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

4.  Human papillomaviruses: a growing field.

Authors:  Denise A Galloway
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

5.  Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Authors:  Subhashini Jagu; Balusubramanyam Karanam; Joshua W Wang; Hatem Zayed; Margit Weghofer; Sarah A Brendle; Karla K Balogh; Kerstin Pino Tossi; Richard B S Roden; Neil D Christensen
Journal:  Vaccine       Date:  2015-09-15       Impact factor: 3.641

6.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

7.  HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.

Authors:  Xiaofei Yan; Depu Wang; Fengli Liang; Ling Fu; Cheng Guo
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

9.  Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18.

Authors:  Valerie Laniosz; Kha C Nguyen; Patricio I Meneses
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.

Authors:  Yan-Xiang Cheng; Gan-Tao Chen; Xiao Yang; Yan-Qing Wang; Li Hong
Journal:  Curr Med Sci       Date:  2018-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.